Cell penetrating peptides and methods of making and using thereof
Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.
1. A cyclic peptide of Formula Ia:
or a pharmaceutically acceptable salt thereof,
wherein m, n and p are independently selected from 0 and 1,
AA 1 , AA 2 , AA 3 , AA 4 , AA 5 , AA 6 , AA 7 , AA 8 , and AA 9 are each independently an amino acid, wherein four or more of the amino acids are arginine, at least four arginines are consecutive, and at least four consecutive amino acids have alternating chirality.
2. The cyclic peptide of claim 1 , wherein the at least four consecutive arginines have alternating chirality.
3. The cyclic peptide of claim 1 , wherein at least one amino acid comprises a hydrophobic aromatic residue.
4. The cyclic peptide of claim 3 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is selected from the group consisting of naphthylalanine, phenylalanine, tryptophan, and tyrosine.
5. The cyclic peptide of claim 4 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is selected from the group consisting of naphthylalanine and phenylalanine.
6. The cyclic peptide of claim 5 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is naphthylalanine.
7. The cyclic peptide of claim 5 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is phenylalanine.
8. The cyclic peptide of claim 1 , wherein the peptide comprises naphthylalanine or phenylalanine.
9. The cyclic peptide of claim 1 , wherein the peptide comprises naphthylalanine and phenylalanine.
10. The cyclic peptide of claim 1 wherein the peptide has a cellular uptake efficiency which is at least about 1.5-fold higher than c(FΦRRRRQ).
11. The cyclic peptide of claim 1 having a structure of:
c(FfΦRrRrQ);
c(fΦRrRrQ);
c(fΦRrRrRQ);
c(FφrRrRq); or
c(FφrRrRQ).
12. A cyclic peptide of claim 1 , wherein:
AA 1 is phenylalanine;
AA 2 is naphthylalanine;
AA 3 is arginine;
AA 4 is arginine;
AA S is arginine; and
AA 6 is arginine.
13. The cyclic peptide according to claim 12 , wherein:
m and n are each 0;
p is 1; and
AA 9 is glutamine.
14. The cyclic peptide according to claim 12 , wherein:
m is 0;
n and p are each 1;
AA 8 is arginine; and
AA 9 is glutamine.
15. The cyclic peptide according to claim 12 , wherein:
m is 0;
n and p are each 1;
AA 8 is glutamine; and
AA 9 is phenylalanine.
16. A cyclic peptide comprising formula IIa, IIb, or IIc:
or a pharmaceutically acceptable salt thereof,
wherein m, n and p are independently selected from 0 and 1,
AA 1 , AA 2 , AA 3 , AA 4 , AA S , AA 6 , AA 7 , AA 8 , and AA 9 are each independently an amino acid, wherein three or more of the amino acids are arginine, and
at least four consecutive amino acids have alternating chirality; and
wherein the cargo moiety comprises a detectable moiety, a therapeutic moiety, a targeting moiety or a combination thereof.
17. The cyclic peptide of claim 16 , wherein at least four of the amino acids are arginine.
18. The cyclic peptide of claim 17 , wherein the at least four arginines are consecutive.
19. The cyclic peptide of claim 18 , wherein the at least four consecutive arginines have alternating chirality.
20. The cyclic peptide of claim 16 , wherein at least one amino acid comprises a hydrophobic aromatic residue.
21. The cyclic peptide of claim 20 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is selected from the group consisting of naphthylalanine, phenylalanine, tryptophan, and tyrosine.
22. The cyclic peptide of claim 21 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is selected from the group consisting of naphthylalanine and phenylalanine.
23. The cyclic peptide of claim 22 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is naphthylalanine.
24. The cyclic peptide of claim 22 , wherein the at least one amino acid comprising the hydrophobic aromatic residue is phenylalanine.
25. The cyclic peptide of claim 16 , wherein the peptide comprises naphthylalanine or phenylalanine.
26. The cyclic peptide of claim 16 , wherein the peptide comprises naphthylalanine and phenylalanine.
27. The cyclic peptide of claim 16 wherein the peptide has a cellular uptake efficiency which is at least about 1.5-fold higher than c(FΦRRRRQ) (SEQ ID NO: 186).
28. A cyclic peptide of claim 16 , wherein
AA 1 is phenylalanine;
AA 2 is naphthylalanine;
AA 3 is arginine;
AA 4 is arginine;
AA S is arginine; and
AA 6 is arginine.
29. The cyclic peptide according to claim 28 , wherein:
m and n are each 0;
p is 1; and
AA 9 is glutamine.
30. The cyclic peptide according to claim 28 , wherein:
m is 0;
n and p are each 1;
AA 8 is arginine; and
AA 9 is glutamine.
31. A method for delivering a therapeutic agent to cytoplasm of a cell, comprising administering at least one cyclic peptide of claim 16 , thereby delivering the therapeutic agent to the cytoplasm of the cell.
32. The method of claim 31 , wherein:
AA 1 is phenylalanine;
AA 2 is naphthylalanine;
AA 3 is arginine;
AA 4 is arginine;
AA S is arginine; and
AA 6 is arginine.
33. The method of claim 32 , wherein:
m and n are each 0;
p is 1; and
AA 9 is glutamine.
34. The method of claim 32 , wherein:
m is 0;
n and p are each 1;
AA 1 is arginine; and
AA 9 is glutamine.
35. The method of claim 32 , wherein:
m is 0;
n and p are each 1;
AA 8 is arginine; and
AA 9 is glutamine.
36. The method of claim 31 , wherein the therapeutic agent is an inhibitor against Ras, PTP1B, Pin1, Grb2, SH2, or combinations thereof.
37. The method of claim 31 , wherein the cyclic peptide further comprises a detectable moiety, a targeting moiety, or a combination thereof.
38. The cyclic peptide of claim 16 , wherein the cargo moiety comprises a therapeutic moiety.
39. The cyclic peptide of claim 16 , wherein
AA 1 is phenylalanine,
AA 2 is phenylalanine;
AA 3 is naphthylalanine;
AA 4 is arginine;
AA S is arginine; and
AA 6 is arginine.
40. The cyclic peptide according to claim 39 , wherein:
m is 0;
n and p are each 1;
AA 8 is arginine; and
AA 9 is glutamine.